![]() |
市場調查報告書
商品編碼
1426980
流感診斷測試市場- 按測試類型(傳統診斷測試{RIDT、DFAT、病毒培養、血清學測定}、分子診斷測定{RT-PCR、LAMP、NASBAT、SAMBA})、最終用途和預測,2023 年- 2032年Influenza Diagnostic Tests Market - By Test Type (Traditional Diagnostic Test {RIDT, DFAT, Viral Culture, Serological Assay}, Molecular Diagnostic Assay {RT-PCR, LAMP, NASBAT, SAMBA}), End-use & Forecast, 2023 - 2032 |
由於全球流感反覆爆發,凸顯了對準確、快速診斷解決方案的迫切需求,預計 2023 年至 2032 年間,流感診斷測試市場的CAGR將達到 6.3%。根據世界衛生組織 2023 年 10 月的報告,每年約有 10 億例季節性流感病例,其中包括 300-500 萬例重症病例。當全世界都在努力應對流感的持續威脅時,診斷測試有助於早期發現、有效治療和遏制病毒。
診斷工具的不斷發展,包括分子檢測、快速抗原檢測和核酸擴增技術,提高了流感診斷的精確度和效率。對更靈敏、更特異和更快速的診斷方法的追求鼓勵了研發投資。
流感診斷測試產業根據測試類型、最終用途和地區進行細分。
分子診斷分析領域有望在預測期內大幅成長,因為聚合酶鏈反應(PCR)和核酸擴增測試在檢測流感病毒方面具有高靈敏度和特異性。這種精確度對於準確和及時的診斷非常重要,可以迅速啟動適當的治療和遏制措施。對快速、可靠的診斷解決方案的需求不斷成長,加上分子診斷技術的進步,促進了該領域的成長。
由於在推進診斷技術和方法方面發揮重要作用,研究實驗室部門將在 2023 年至 2032 年期間為市場帶來可觀的收入。研究實驗室幫助開發創新的診斷方法和不斷改進現有的測試平台。研究實驗室對卓越診斷準確性的追求直接轉化為更可靠、更有效率的測試的可用性,從而提高了診斷能力的整體標準。
由於快速的城市化、醫療保健意識的提高以及政府積極主動對抗傳染病,亞太地區流感診斷測試行業預計到 2032 年將顯著成長。流感發生率的增加,加上人們對傳染病的經濟影響的認知不斷提高,刺激了對精確診斷解決方案的需求。此外,醫療機構、政府和診斷公司之間的策略合作有助於更有效地應對流感疫情,有利於區域市場前景。
Influenza Diagnostic Tests Market is estimated to witness 6.3% CAGR between 2023 and 2032, owing to the recurrent global outbreaks of influenza that highlight the critical need for accurate and rapid diagnostic solutions. As per WHO October 2023 report, there were approximately a billion cases of seasonal influenza annually, which included 3-5 million cases of severe illness. As the world grapples with the ongoing threat of influenza, diagnostic tests help in early detection, effective treatment, and containment of the virus.
The continual evolution of diagnostic tools, including molecular assays, rapid antigen tests, and nucleic acid amplification techniques, enhances the precision and efficiency of influenza diagnosis. The quest for more sensitive, specific, and quicker diagnostic methods encourages R&D investments.
Influenza diagnostic tests industry is segmented on the basis of test type, end-use, and region.
Molecular diagnostic assays segment is poised for substantial growth over the forecast period, as polymerase chain reaction (PCR) and nucleic acid amplification tests, offer high sensitivity and specificity in detecting influenza viruses. This precision is important for accurate and timely diagnosis, allowing for prompt initiation of appropriate treatments and containment measures. The growing demand for rapid and reliable diagnostic solutions, coupled with advancements in molecular diagnostic technologies, contribute to the segment growth.
Research laboratories segment will generate notable revenues for the market during 2023-2032, owing to the instrumental role in advancing diagnostic technologies and methodologies. Research laboratories help in the development of innovative diagnostic assays and the continual improvement of existing testing platforms. The pursuit of excellence in diagnostic accuracy within research laboratories directly translates into the availability of more reliable and efficient tests, elevating the overall standard of diagnostic capabilities.
Asia Pacific influenza diagnostic tests industry is slated to witness a significant growth rate through 2032, attributed to rapid urbanization, increased healthcare awareness, and proactive government initiatives to combat infectious disease. The increasing incidence of influenza, coupled with a rising awareness of the economic impact of infectious diseases, fuels the demand for precise diagnostic solutions. Moreover, strategic collaborations between healthcare institutions, governments, and diagnostic companies contribute to a more efficient response to influenza outbreaks, favoring the regional market outlook.